Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Myrcludex-B (Primary) ; Peginterferon alfa
- Indications Hepatitis B; Hepatitis D
- Focus Proof of concept; Therapeutic Use
- Sponsors Hepatera
- 16 Aug 2017 Status changed from active, no longer recruiting to completed.
- 15 Nov 2016 Final results presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases
- 27 Apr 2016 Interim results published in the Journal of Hepatology.